ELI LILLY AND COMPANY Cost of Revenue
ELI LILLY AND COMPANY (LLY) reported Cost of Revenue of $3.27 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- ELI LILLY AND COMPANY cost of goods and services sold for the quarter ending 2026-06-30 was $3.27B, a 33.50% increase year-over-year.
- ELI LILLY AND COMPANY cost of goods and services sold for the quarter ending 2026-03-31 was $3.58B, a 60.76% increase year-over-year.
- ELI LILLY AND COMPANY cost of goods and services sold for the quarter ending 2025-12-31 was $3.37B, a 40.28% increase year-over-year.
- ELI LILLY AND COMPANY cost of goods and services sold for the quarter ending 2025-09-30 was $3.01B, a 38.58% increase year-over-year.
- ELI LILLY AND COMPANY cost of goods and services sold for fiscal 2025 was $11.05B, a 31.29% increase from fiscal 2024.
- ELI LILLY AND COMPANY cost of goods and services sold for fiscal 2024 was $8.42B, a 18.86% increase from fiscal 2023.
- ELI LILLY AND COMPANY cost of goods and services sold for fiscal 2023 was $7.08B, a 6.82% increase from fiscal 2022.
- ELI LILLY AND COMPANY cost of goods and services sold for fiscal 2022 was $6.63B, a 9.34% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.27B 10-Q · filed 2026-08-05 | $6.84B 10-Q · filed 2026-08-05 | $10.22B derived: sum of 3 quarters · filed 2026-08-05 | $13.22B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $3.58B 10-Q · filed 2026-04-30 | $6.95B derived: sum of 2 quarters · filed 2026-04-30 | $9.96B derived: sum of 3 quarters · filed 2026-04-30 | $12.40B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $3.37B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $6.38B derived: sum of 2 quarters · filed 2026-02-12 | $8.83B derived: sum of 3 quarters · filed 2026-08-05 | $11.05B 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $3.01B 10-Q · filed 2025-10-30 | $5.46B derived: sum of 2 quarters · filed 2026-08-05 | $7.68B 10-Q · filed 2025-10-30 | $10.08B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $2.45B 10-Q · filed 2026-08-05 | $2.45B 10-Q · filed 2025-08-07 | $4.67B 10-Q · filed 2026-08-05 | $7.08B derived: sum of 3 quarters · filed 2026-08-05 | $9.25B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $2.23B 10-Q · filed 2026-04-30 | $2.22B 10-Q · filed 2025-05-01 | $4.63B derived: sum of 2 quarters · filed 2026-04-30 | $6.80B derived: sum of 3 quarters · filed 2026-04-30 | $8.97B derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2024-12-31 | $2.40B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $4.57B derived: sum of 2 quarters · filed 2026-02-12 | $6.74B derived: sum of 3 quarters · filed 2026-02-12 | $8.42B 10-K · filed 2026-02-12 | $8.42B 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $2.17B 10-Q · filed 2025-10-30 | $4.34B derived: sum of 2 quarters · filed 2025-10-30 | $6.01B 10-Q · filed 2025-10-30 | $7.80B derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $2.17B 10-Q · filed 2025-08-07 | $3.84B 10-Q · filed 2025-08-07 | $5.63B derived: sum of 3 quarters · filed 2026-02-12 | $7.49B derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $1.67B 10-Q · filed 2025-05-01 | $3.46B derived: sum of 2 quarters · filed 2026-02-12 | $5.32B derived: sum of 3 quarters · filed 2026-02-12 | $7.13B derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $1.79B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $3.65B derived: sum of 2 quarters · filed 2026-02-12 | $5.46B derived: sum of 3 quarters · filed 2026-02-12 | $7.08B 10-K · filed 2026-02-12 | $7.08B 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $1.86B 10-Q · filed 2024-10-30 | $3.67B derived: sum of 2 quarters · filed 2024-10-30 | $5.29B 10-Q · filed 2024-10-30 | $6.84B derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $1.81B 10-Q · filed 2024-08-08 | $3.43B 10-Q · filed 2024-08-08 | $4.98B derived: sum of 3 quarters · filed 2025-02-19 | $6.56B derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $1.63B 10-Q · filed 2024-04-30 | $3.17B derived: sum of 2 quarters · filed 2025-02-19 | $4.75B derived: sum of 3 quarters · filed 2025-02-19 | $6.18B derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $1.55B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $3.13B derived: sum of 2 quarters · filed 2025-02-19 | $4.56B derived: sum of 3 quarters · filed 2025-02-19 | $6.63B 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | $1.58B 10-Q · filed 2023-11-02 | $3.01B derived: sum of 2 quarters · filed 2023-11-02 | $5.08B 10-Q · filed 2023-11-02 | $7.13B derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $1.43B 10-Q · filed 2023-08-08 | $3.50B 10-Q · filed 2023-08-08 | $5.55B derived: sum of 3 quarters · filed 2024-02-21 | $6.98B derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | $2.07B 10-Q · filed 2023-04-27 | $4.12B derived: sum of 2 quarters · filed 2024-02-21 | $5.55B derived: sum of 3 quarters · filed 2024-02-21 | $7.51B derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $2.05B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $3.48B derived: sum of 2 quarters · filed 2024-02-21 | $5.43B derived: sum of 3 quarters · filed 2024-02-21 | $7.31B 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $1.43B 10-Q · filed 2022-11-01 | $3.38B derived: sum of 2 quarters · filed 2022-11-01 | $5.26B 10-Q · filed 2022-11-01 | $6.98B derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $1.95B 10-Q · filed 2022-08-04 | $3.83B 10-Q · filed 2022-08-04 | $5.55B derived: sum of 3 quarters · filed 2023-02-22 | $6.88B derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $1.88B 10-Q · filed 2022-04-29 | $3.60B derived: sum of 2 quarters · filed 2023-02-22 | $4.92B derived: sum of 3 quarters · filed 2023-02-22 | $6.15B derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $1.72B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $3.05B derived: sum of 2 quarters · filed 2023-02-22 | $4.27B derived: sum of 3 quarters · filed 2023-02-22 | $5.48B 10-K · filed 2023-02-22 | ||||
| 2020-09-30 | $1.33B 10-Q · filed 2021-10-27 | $2.55B derived: sum of 2 quarters · filed 2021-10-27 | $3.76B 10-Q · filed 2021-10-27 | $5.05B derived: sum of 4 quarters · filed 2021-10-27 | ||||
| 2020-06-30 | $1.22B 10-Q · filed 2021-08-03 | $2.44B 10-Q · filed 2021-08-03 | $3.72B derived: sum of 3 quarters · filed 2021-08-03 | $4.89B derived: sum of 4 quarters · filed 2021-08-03 | ||||
| 2020-03-31 | $1.22B 10-Q · filed 2021-04-30 | $2.50B derived: sum of 2 quarters · filed 2021-04-30 | $3.67B derived: sum of 3 quarters · filed 2021-04-30 | $4.80B derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $1.28B 10-K · filed 2020-02-19 | $2.46B derived: sum of 2 quarters · filed 2020-10-28 | $3.58B derived: sum of 3 quarters · filed 2020-10-28 | $4.72B 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | $1.18B 10-Q · filed 2020-10-28 | $2.30B derived: sum of 2 quarters · filed 2020-10-28 | $3.44B 10-Q · filed 2020-10-28 | $4.57B derived: sum of 4 quarters · filed 2020-10-28 | ||||
| 2019-06-30 | $1.12B 10-Q · filed 2020-07-31 | $2.26B 10-Q · filed 2020-07-31 | $3.39B derived: sum of 3 quarters · filed 2020-07-31 | $4.55B derived: sum of 4 quarters · filed 2020-07-31 | ||||
| 2019-03-31 | $1.14B 10-Q · filed 2020-05-01 | $2.27B derived: sum of 2 quarters · filed 2020-05-01 | $3.42B derived: sum of 3 quarters · filed 2020-05-01 | $4.66B derived: sum of 4 quarters · filed 2020-05-01 | ||||
| 2018-12-31 | $1.13B 10-K · filed 2020-02-19 | $1.59B 10-K · filed 2019-02-19 | $2.28B derived: sum of 2 quarters · filed 2020-02-19 | $3.52B derived: sum of 3 quarters · filed 2020-02-19 | $4.68B 10-K · filed 2021-02-17 | $6.43B 10-K · filed 2019-02-19 | ||
| 2018-09-30 | $1.15B 10-K · filed 2020-02-19 | $1.56B 10-Q · filed 2018-11-06 | $2.39B derived: sum of 2 quarters · filed 2020-02-19 | $3.55B 10-Q · filed 2019-10-25 | $4.84B 10-Q · filed 2018-11-06 | $4.74B derived: sum of 4 quarters · filed 2020-02-19 | ||
| 2018-06-30 | $1.23B 10-K · filed 2020-02-19 | $1.70B 10-Q · filed 2018-07-25 | $2.40B 10-Q · filed 2019-08-02 | $3.27B 10-Q · filed 2018-07-25 | $3.59B derived: sum of 3 quarters · filed 2020-02-19 | $4.75B derived: sum of 4 quarters · filed 2020-02-19 | ||
| 2018-03-31 | $1.16B 10-K · filed 2020-02-19 | $1.57B 10-K · filed 2019-02-19 | $2.35B derived: sum of 2 quarters · filed 2020-02-19 | $3.51B derived: sum of 3 quarters · filed 2020-02-19 | $4.65B derived: sum of 4 quarters · filed 2020-02-19 | |||
| 2017-12-31 | $1.19B 8-K · filed 2019-10-24 | $1.64B 10-K · filed 2019-02-19 | $2.35B derived: sum of 2 quarters · filed 2019-10-24 | $3.49B derived: sum of 3 quarters · filed 2019-10-24 | $4.45B 10-K · filed 2020-02-19 | $6.15B 10-K · filed 2019-02-19 | ||
| 2017-09-30 | $1.16B 8-K · filed 2019-10-24 | $1.59B 10-Q · filed 2018-11-06 | $2.30B derived: sum of 2 quarters · filed 2019-10-24 | $4.51B 10-Q · filed 2018-11-06 | ||||
| 2017-06-30 | $1.14B 8-K · filed 2019-10-24 | $1.57B 10-Q · filed 2018-07-25 | $2.92B 10-Q · filed 2018-07-25 | |||||
| 2017-03-31 | $957.70M 8-K · filed 2019-10-24 | $1.35B 10-K · filed 2019-02-19 | ||||||
| 2016-12-31 | $4.16B 8-K · filed 2019-10-24 | $5.71B 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |